Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
Company with NASH Candidate in Ph IIb Trials Updates $86 Million IPO filing
CP Wire
Thu, 02/14/19 - 09:40 am
Cirius Therapeutics
NASH
MSDC-0602K
IPOs
Company with NASH Candidate in Ph IIb Trials Updates $86 Million IPO filing
Thu, 02/14/19 - 09:38 am
Cirius Therapeutics
NASH
MSDC-0602K
Ascletis Acquires Rights to PH II NASH Candidate
CP Wire
Thu, 02/14/19 - 12:14 am
NASH
Ascletis Pharmaceuticals
3-V Biosciences
It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial
Endpoints
Mon, 02/11/19 - 08:06 pm
Gilead Sciences
NASH
selonsertib
clinical trials
Microbiome Report for Week Ending 1/26/19
CP Wire
Tue, 01/29/19 - 03:39 pm
microbiome
Second Genome
Vedanta Biosciences
NASH
Immune Biotech
Evotec Receives Milestone Payment for Beginning Phase II NASH Clinical Trial
CP Wire
Thu, 01/24/19 - 10:51 am
Evotec
Second Genome
NASH
SGM-1019
Evotec Receives Milestone Payment for Beginning Phase II NASH Clinical Trial
Thu, 01/24/19 - 10:12 am
Evotec
Second Genome
NASH
SGM-1019
What’s up with all the buzz about Gilead’s PhIII NASH drug selonsertib?
Endpoints
Wed, 01/23/19 - 08:02 pm
clinical trials
NASH
Gilead Sciences
selonsertib
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
Tue, 01/22/19 - 11:52 am
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Lipocine talks up interim data from small NASH study
Fierce Biotech
Thu, 01/17/19 - 10:07 am
Lipocine
NASH
LPCN 1144
clinical trials
NASH Space in Focus in 2019 as Firms Look to Diversify
Yahoo/Zacks.com
Sun, 01/13/19 - 11:32 am
NASH
Gilead Sciences
Merck
Roche
Novartis
Jecure Therapeutics
Pfizer
Celgene
Eli Lilly
Gilead Inks $785 Million Deal With Yuhan for NASH Development
BioSpace
Mon, 01/7/19 - 11:16 am
Gilead Sciences
NASH
South Korea
Yuhan
Merck bags global rights to NGM NASH drug, plans phase 2b trial
Fierce Biotech
Thu, 01/3/19 - 09:45 am
Merck
NASH
NGM Biopharmaceuticals
type 2 diabetes
clinical trials
MK-3655
Gilead dangles $105M in quick cash to sign Scholar Rock to a discovery deal for its growing NASH pipeline
Endpoints
Wed, 12/19/18 - 10:39 am
Gilead Sciences
NASH
Scholar Rock
Upstart Akero continues its swoosh into NASH space with $70M windfall round
Endpoints
Wed, 12/12/18 - 07:01 pm
Akero Therapeutics
NASH
AKR-001
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Motley Fool
Sun, 12/9/18 - 03:55 pm
Madrigal Pharmaceuticals
NASH
MGL-3196
Viking Therapeutics
VK2809
CEO of Chapel Hill firm talks 2 new partnerships with big pharma
Bizjournals
Sat, 12/8/18 - 10:31 am
Target PharmaSolutions
Gilead Sciences
Bristol-Myers Squibb
hepatitis B
NASH
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
Endpoints
Thu, 12/6/18 - 10:02 am
Genfit
NASH
Gilead Sciences
Intercept Pharma
clinical trials
elafibranor
Novartis’ partners at Conatus have another NASH setback to confess today
Endpoints
Wed, 12/5/18 - 07:43 pm
Novartis
Conatus
emricasan
cirrhosis
NASH
clinical trials
FDA Issues Draft Guidance on NASH Drug Development
RAPS.org
Mon, 12/3/18 - 11:00 pm
FDA
NASH
Pages
« first
‹ previous
…
6
7
8
9
10
11
12
13
14
next ›
last »